Intelligent Bio Solutions (NASDAQ:INBS) vs. DexCom (NASDAQ:DXCM) Head to Head Review

DexCom (NASDAQ:DXCM – Get Free Report) and Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Institutional & Insider Ownership

97.8% of DexCom shares are owned by institutional investors. Comparatively, 33.0% of Intelligent Bio Solutions shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 2.8% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for DexCom and Intelligent Bio Solutions, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom 0 2 24 2 3.00
Intelligent Bio Solutions 1 1 0 0 1.50

DexCom presently has a consensus target price of $95.50, indicating a potential upside of 16.41%. Given DexCom’s stronger consensus rating and higher possible upside, equities research analysts clearly believe DexCom is more favorable than Intelligent Bio Solutions.

Earnings and Valuation

This table compares DexCom and Intelligent Bio Solutions”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DexCom $4.66 billion 6.56 $836.30 million $2.55 32.17
Intelligent Bio Solutions $4.22 million 1.23 -$12.43 million ($6.38) -0.24

DexCom has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares DexCom and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DexCom 19.42% 37.77% 15.98%
Intelligent Bio Solutions -269.28% -150.00% -83.38%

Risk & Volatility

DexCom has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.48, meaning that its share price is 348% more volatile than the S&P 500.

Summary

DexCom beats Intelligent Bio Solutions on 13 of the 15 factors compared between the two stocks.

About DexCom

(Get Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

About Intelligent Bio Solutions

(Get Free Report)

Intelligent Bio Solutions Inc. is a medical technology company focused on non-invasive testing and diagnostic solutions. Its flagship offering is the Intelligent Fingerprinting Drug Screening System, which analyzes trace sweat collected from a person’s fingertips to screen for drugs. The system combines a portable reader with single-use fingerprint test cartridges. Its compact format is designed for use in settings such as workplaces, law enforcement, drug treatment and rehabilitation programs, and other organizations that conduct screening.

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.